Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer - PubMed
6 hours ago
- #Immunotherapy
- #Real-world Evidence
- #Small Cell Lung Cancer
- Tarlatamab is a standard second-line therapy for small cell lung cancer (SCLC), but real-world outcomes for trial-ineligible patients are not well-understood.
- A multicenter retrospective study of 102 SCLC patients treated with tarlatamab found 59% would have been ineligible for clinical trials due to factors like poor performance status or organ dysfunction.
- Trial-eligible patients (n=34) had better efficacy outcomes, with 70% achieving partial response or stable disease vs. 57% progressive disease in ineligible patients (p=0.047), and longer median time on treatment (4.8 vs. 2.1 months, p=0.06).
- Cytokine release syndrome (CRS) incidence was similar between groups (63% vs. 59%, p=0.8), but immune effector cell-associated neurotoxicity (ICANS) was more common in ineligible patients (33% vs. 14%, p=0.038).
- The study concludes tarlatamab can be broadly applied to trial-ineligible patients, though with potentially lower efficacy and higher neurotoxicity risk.